Skip to main content
Top
Published in: Osteoporosis International 11/2011

01-11-2011 | Short Commmunication

The anti-tumor agent sagopilone shows antiresorptive effects both in vitro and in vivo

Authors: A. Strube, M. I. Suominen, J. P. Rissanen, D. Mumberg, U. Klar, J. M. Halleen, S.-M. Käkönen

Published in: Osteoporosis International | Issue 11/2011

Login to get access

Abstract

Summary

Sagopilone, a fully synthetic epothilone and very potent anti-tumor agent, has proved to be efficient in inhibiting bone destruction and tumor burden in a mouse model of breast cancer bone metastasis. In addition to its antiproliferative effects, this study shows direct effects of sagopilone on bone resorption and osteoclast activity.

Introduction

Sagopilone, a novel fully synthetic third-generation epothilone, has proved to be efficient in inhibiting bone destruction and tumor burden in a mouse model of breast cancer bone metastasis. The aim of this study was to investigate whether the effect was primarily due to sagopilone’s antiproliferative effect and consequent inhibition of tumor cell growth, or if sagopilone exerts direct effects on bone resorption and osteoclast activity.

Methods

Sagopilone was studied and compared to paclitaxel in vitro in human osteoclast differentiation and activity cultures. For studying the potential of sagopilone for inhibiting bone resorption in vivo, a mouse model of ovariectomy (ovx)-induced osteoporosis was utilized.

Results

Sagopilone inhibited osteoclast differentiation and activity more efficiently than paclitaxel and showed less cytotoxicity. Whereas sagopilone showed inhibitory effects on human osteoclast differentiation and activity already at 5 and 15 nM, respectively, paclitaxel started to show effects only at 20 and 100 nM concentrations, respectively. Sagopilone treatment increased BMD In the mouse ovx model even though a non-optimized dose was used which is effective in tumor-bearing mice.

Conclusion

This is the first study to evaluate sagopilone’s effects on bone resorption in non-cancerous situation. The evidence that sagopilone is beneficial for bone will strengthen the status of sagopilone as an anti-cancer compound compared to other microtubule stabilizing agents.
Literature
1.
go back to reference Saad F, Adachi JD, Brown JP, Canning LA, Gelmon KA, Josse RG, Pritchard KI (2008) Cancer treatment-induced bone loss in breast and prostate cancer. J Clin Oncol 26:5465–5476PubMedCrossRef Saad F, Adachi JD, Brown JP, Canning LA, Gelmon KA, Josse RG, Pritchard KI (2008) Cancer treatment-induced bone loss in breast and prostate cancer. J Clin Oncol 26:5465–5476PubMedCrossRef
2.
go back to reference Shapiro CL, Recht A (2001) Side effects of adjuvant treatment of breast cancer. N Engl J Med 344:1997–2008PubMedCrossRef Shapiro CL, Recht A (2001) Side effects of adjuvant treatment of breast cancer. N Engl J Med 344:1997–2008PubMedCrossRef
3.
go back to reference Zheng Y, Zhou H, Modzelewski JR, Kalak R, Blair JM, Seibel MJ, Dunstan CR (2007) Accelerated bone resorption, due to dietary calcium deficiency, promotes breast cancer tumor growth in bone. Cancer Res 67(19):9542–9548PubMedCrossRef Zheng Y, Zhou H, Modzelewski JR, Kalak R, Blair JM, Seibel MJ, Dunstan CR (2007) Accelerated bone resorption, due to dietary calcium deficiency, promotes breast cancer tumor growth in bone. Cancer Res 67(19):9542–9548PubMedCrossRef
4.
go back to reference Zheng Y, Zhou H, Fong-Yee C, Modzelewski JR, Seibel MJ, Dunstan CR (2008) Bone resorption increases tumour growth in a mouse model of osteosclerotic breast cancer metastasis. Clin Exp Metastasis 25(5):559–567PubMedCrossRef Zheng Y, Zhou H, Fong-Yee C, Modzelewski JR, Seibel MJ, Dunstan CR (2008) Bone resorption increases tumour growth in a mouse model of osteosclerotic breast cancer metastasis. Clin Exp Metastasis 25(5):559–567PubMedCrossRef
5.
go back to reference Tu Q, Zhang J, Fix A, Brewer E, Li Y-P, Zhang Z, Chen J (2009) Targeted overexpression of BSP in osteoclasts promotes bone metastasis of breast cancer cells. J Cell Physiol 218(1):135–145PubMedCrossRef Tu Q, Zhang J, Fix A, Brewer E, Li Y-P, Zhang Z, Chen J (2009) Targeted overexpression of BSP in osteoclasts promotes bone metastasis of breast cancer cells. J Cell Physiol 218(1):135–145PubMedCrossRef
7.
go back to reference Klar U, Buchmann B, Schwede W, Skuballa W, Hoffmann J, Lichtner RB (2006) Total synthesis and antitumor activity of ZK-EPO: the first fully synthetic epothilone in clinical development. Angew Chem Int Ed Engl 45:7942–7948PubMedCrossRef Klar U, Buchmann B, Schwede W, Skuballa W, Hoffmann J, Lichtner RB (2006) Total synthesis and antitumor activity of ZK-EPO: the first fully synthetic epothilone in clinical development. Angew Chem Int Ed Engl 45:7942–7948PubMedCrossRef
9.
go back to reference Hoffmann J, Vitale I, Buchmann B, Galluzzi L, Schwede W, Senovilla L, Skuballa W, Vivet S, Lichtner RB, Vicencio JM et al (2008) Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone. Cancer Res 68:5301–5308PubMedCrossRef Hoffmann J, Vitale I, Buchmann B, Galluzzi L, Schwede W, Senovilla L, Skuballa W, Vivet S, Lichtner RB, Vicencio JM et al (2008) Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone. Cancer Res 68:5301–5308PubMedCrossRef
10.
go back to reference Hammer S, Sommer A, Fichtner I, Becker M, Rolff J, Merk J, Klar U, Hoffmann J (2010) Comparative profiling of the novel epothilone, sagopilone, in xenografts derived from primary non-small cell lung cancer. Clin Cancer Res 16:1452–1465PubMedCrossRef Hammer S, Sommer A, Fichtner I, Becker M, Rolff J, Merk J, Klar U, Hoffmann J (2010) Comparative profiling of the novel epothilone, sagopilone, in xenografts derived from primary non-small cell lung cancer. Clin Cancer Res 16:1452–1465PubMedCrossRef
11.
go back to reference Arnold D, Voigt W, Kiewe P, Behrmann C, Lindemann S, Reif S, Wiesinger H, Giurescu M, Thiel E, Schmoll HJ (2009) Weekly administration of sagopilone (ZK-EPO), a fully synthetic epothilone, in patients with refractory solid tumours: results of a phase I trial. Br J Cancer 101:1241–1247PubMedCrossRef Arnold D, Voigt W, Kiewe P, Behrmann C, Lindemann S, Reif S, Wiesinger H, Giurescu M, Thiel E, Schmoll HJ (2009) Weekly administration of sagopilone (ZK-EPO), a fully synthetic epothilone, in patients with refractory solid tumours: results of a phase I trial. Br J Cancer 101:1241–1247PubMedCrossRef
12.
go back to reference Schmid P, Kiewe P, Possinger K, Korfel A, Lindemann S, Giurescu M, Reif S, Wiesinger H, Thiel E, Kühnhardt D (2010) Phase I study of the novel, fully synthetic epothilone sagopilone (ZK-EPO) in patients with solid tumors. Ann Oncol 21:633–639PubMedCrossRef Schmid P, Kiewe P, Possinger K, Korfel A, Lindemann S, Giurescu M, Reif S, Wiesinger H, Thiel E, Kühnhardt D (2010) Phase I study of the novel, fully synthetic epothilone sagopilone (ZK-EPO) in patients with solid tumors. Ann Oncol 21:633–639PubMedCrossRef
13.
go back to reference Silvani A, Gaviani P, Fiumani A, Scaioli V, Lamperti E, Eoli M, Botturi A, Salmaggi A (2009) Systemic sagopilone (ZK-EPO) treatment of patients with recurrent malignant gliomas. J Neurooncol 95:61–64PubMedCrossRef Silvani A, Gaviani P, Fiumani A, Scaioli V, Lamperti E, Eoli M, Botturi A, Salmaggi A (2009) Systemic sagopilone (ZK-EPO) treatment of patients with recurrent malignant gliomas. J Neurooncol 95:61–64PubMedCrossRef
14.
go back to reference Strube A, Hoffmann J, Stepina E, Hauff P, Klar U, Käkönen SM (2009) Sagopilone (ZK-EPO) inhibits breast cancer bone metastasis and bone destruction due to simultaneous inhibition of both tumor growth and bone resorption. Clin Cancer Res 15:3751–3759PubMedCrossRef Strube A, Hoffmann J, Stepina E, Hauff P, Klar U, Käkönen SM (2009) Sagopilone (ZK-EPO) inhibits breast cancer bone metastasis and bone destruction due to simultaneous inhibition of both tumor growth and bone resorption. Clin Cancer Res 15:3751–3759PubMedCrossRef
15.
go back to reference Rissanen JP, Suominen MI, Peng Z, Halleen JM (2008) Secreted tartrate-resistant acid phosphatase 5b is a Marker of osteoclast number in human osteoclast cultures and the rat ovariectomy model. Calcif Tissue Int 82:108–115PubMedCrossRef Rissanen JP, Suominen MI, Peng Z, Halleen JM (2008) Secreted tartrate-resistant acid phosphatase 5b is a Marker of osteoclast number in human osteoclast cultures and the rat ovariectomy model. Calcif Tissue Int 82:108–115PubMedCrossRef
16.
go back to reference Everts V, Delaissé JM, Korper W, Niehof A, Vaes G, Beertsen W (1992) Degradation of collagen in the bone-resorbing compartment underlying the osteoclast involves both cysteine-proteinases and matrix metalloproteinases. J Cell Physiol 150:221–231PubMedCrossRef Everts V, Delaissé JM, Korper W, Niehof A, Vaes G, Beertsen W (1992) Degradation of collagen in the bone-resorbing compartment underlying the osteoclast involves both cysteine-proteinases and matrix metalloproteinases. J Cell Physiol 150:221–231PubMedCrossRef
17.
go back to reference Hall TJ, Jeker H, Schaueblin M (1995) Taxol inhibits osteoclastic bone resorption. Calcif Tissue Int 57:463–465PubMedCrossRef Hall TJ, Jeker H, Schaueblin M (1995) Taxol inhibits osteoclastic bone resorption. Calcif Tissue Int 57:463–465PubMedCrossRef
18.
go back to reference Davis HW, VandenBerg E, Reid MD, Roy-Chaudhury P, Edwards JD (2005) Paclitaxel impairs endothelial cell adhesion but not cytokine-induced cellular adhesion molecule expression. Ann Vasc Surg 19:398–406PubMedCrossRef Davis HW, VandenBerg E, Reid MD, Roy-Chaudhury P, Edwards JD (2005) Paclitaxel impairs endothelial cell adhesion but not cytokine-induced cellular adhesion molecule expression. Ann Vasc Surg 19:398–406PubMedCrossRef
19.
go back to reference Jimi E, Nakamura I, Amano H, Taguchi Y, Tsurukai T, Tamura M, Takahashi N, Suda T (1996) Osteoclast function is activated by osteoblastic cells through a mechanism involving cell-to-cell contact. Endocrinology 137(8):2187–2190CrossRef Jimi E, Nakamura I, Amano H, Taguchi Y, Tsurukai T, Tamura M, Takahashi N, Suda T (1996) Osteoclast function is activated by osteoblastic cells through a mechanism involving cell-to-cell contact. Endocrinology 137(8):2187–2190CrossRef
20.
21.
go back to reference Vaananen HK, Laitala-Leinonen T (2008) Osteoclast lineage and function. Arch Biochem Biophys 473:132–138PubMedCrossRef Vaananen HK, Laitala-Leinonen T (2008) Osteoclast lineage and function. Arch Biochem Biophys 473:132–138PubMedCrossRef
22.
go back to reference Pfeilschifter J, Diel IJ (2000) Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol 18:1570–1593PubMed Pfeilschifter J, Diel IJ (2000) Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol 18:1570–1593PubMed
Metadata
Title
The anti-tumor agent sagopilone shows antiresorptive effects both in vitro and in vivo
Authors
A. Strube
M. I. Suominen
J. P. Rissanen
D. Mumberg
U. Klar
J. M. Halleen
S.-M. Käkönen
Publication date
01-11-2011
Publisher
Springer-Verlag
Published in
Osteoporosis International / Issue 11/2011
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-010-1486-9

Other articles of this Issue 11/2011

Osteoporosis International 11/2011 Go to the issue